Graphenea Semiconductor, a leading graphene foundry company and Melexis (Euronext Brussels: MELE), a global supplier of micro-electronic semiconductor solutions, have announced a strategic collaboration to accelerate the development and evaluation of Melexis’ integrated GFET-on-CMOS platform for advanced biosensing.
The initiative aims to address some of the key challenges in biosensor adoption: simplifying complex readout electronics and improving sensitivity while ensuring reliability and scalability. By combining Melexis’ expertise in semiconductor integration with Graphenea’s knowhow in graphene transistors, the collaboration represents a step from laboratory prototypes to real-world deployment. Potential applications include medical diagnostics, such as cancer biomarker detection, neurological and infectious diseases detection, and broader biosensing applications like environmental sensing of PFAS.
Jesus de la Fuente, CEO of Graphenea Semiconductor, said: “This collaboration with Melexis is a significant step forward for the biosensor field. Graphene has long been recognized for its extraordinary sensitivity, but system integration remained a challenge. Melexis’ GFET-on-CMOS platform bridges that gap, and together we are laying the foundation for practical, reliable graphene-based diagnostic tools.”
Axel Fanget, Product Line Manager at Melexis, said: “This collaboration with Graphenea is essential to validate and accelerate the development of our integrated biosensing platform. By working directly with graphene and biosensor specialists, we will significantly enhance our capacity to deliver user-friendly, high-performance, and cost-effective solutions with the potential to revolutionize healthcare and in-vitro diagnostics.”
